Skip to content

Tranexamic acid to reduce bleeding after cesarean section in high risk patients.

Role of Tranexamic acid in reducing the use of uterotonic drugs in parturients at increased risk for obstetric haemorrhage undergoing cesarean section.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/05/005752
Enrollment
60
Registered
2015-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pregnant women planned for cesarean delivery

Interventions

Intervention1: Tranexamic acid: 10 mg / kg diluted to 20 ml with normal saline given IV 10 min prior to skin incision Control Intervention1: Normal saline: 20 ml given IV 10 min prior to skin incision

Sponsors

Max Super Speciality Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant women at high risk for bleeding planned for cesarean delivery.

Exclusion criteria

Exclusion criteria: history of ischemic cardiac disease, hemodynamic instability before commencement of surgery, bleeding disorders, known allergy to tranexamic acid, history of any thrombogenic episodes, patients on anticoagulants history of kidney disease history of hematuria

Design outcomes

Primary

MeasureTime frame
to find the need for additional uterotonic drugs in the first 24 hours postpartum in women at increased risk for obstetric hemorrhageTimepoint: from start of cesarean section till 24 hours after baby delivery

Secondary

MeasureTime frame
The secondary objectives were to compare between the two groups the estimated blood loss, requirement for blood transfusion, any neonatal adverse events or thrombogenic episodes in the mother.Timepoint: from start of cesarean section till 24 hours after baby delivery

Countries

India

Contacts

Public ContactNambiath Sujata

Department of Anesthesiology, Max Super Speciality Hospital

drranjeetkaur@hotmail.com9999109402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 2, 2026